Cutaneous Cholesterol Emboli with Infarction Clinically Mimicking Heparin Necrosis -- A Case Report

Zaytsev, Polina; Miller, Kenneth; Pellettiere, Edmund V.
June 1986
Angiology;Jun1986, Vol. 37 Issue 6, p471
Academic Journal
Cutaneous necrosis secondary to anticoagulation (heparin and warfarin) and cholesterol (atheromatous) emboli can be similar clinically and histologically. A unique case is reported of cholesterol emboli clinically mimicking heparin necrosis. The patient was a 57 year old white male who underwent coronary angioplasty and was treated with intravenous heparin Shortly after he developed large ecchymotic areas at the level of the umbilicus and distally which progressed to eschar. Renal failure ensued and he died secondary to stress ulcers. Cholesterol emboli were demonstrated in small muscular arteries of the dermis and panniculus along with a full thickness infarct. Because of the increasing popularity of angioplasty utilizing a retrograde femoral approach plus heparin anticoagulation, it is important to recognize the difficulty in making a clinical diagnosis when cutaneous necrosis supervenes. An incisional biopsy of the skin is recommended.


Related Articles

  • LMWH as Bridge Anticoagulation During Warfarin Interruption. Miller, Karl E. // American Family Physician;4/15/2005, Vol. 71 Issue 8, p1599 

    Presents an abstract of the study "Molecular-Weight Heparin As Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulant Regimen," by J. D. Douketis and colleagues, published in the June 28, 2004 issue of "Archives of Internal Medicine."

  • Anticoagulation. Fay, Matt; Fry, Mandy // Pulse;Sep2015, p84 

    The article presents questions and answers related to heparin, the new oral anticoagulants(NOACs) and the time when anticoagulation should stop including why NOACs are licensed for non-valvular atrial fibrillation, the choice between NOAC and warfarin, are NOACs safer for poor compliance patients.

  • Bivalirudin superior to heparin in pre-hospital setting for patients with STEMI.  // Cardiology Today;Dec2013, Vol. 16 Issue 12, p16 

    The article discusses findings of a EUROMAX trial indicating better outcomes with ST segment evaluation myocardial infarction (STEMI) anticoagulant bivalirudin in patients who need percutaneous coronary intervention (PCI) as compared to using heparin with or without glycoprotein IIb/IIa inhibitors.

  • Efficient use of bridge anticoagulation therapy. Perez, Mirza E.; Graham, Mark G.; Sivaraman, Priya // Patient Care;Oct2006, Vol. 40 Issue 10, p38 

    The article discusses the efficiency of using anticoagulation therapy for the treatment and prevention of thromboembolism. Warfarin has anticoagulation affects. There are several options for the periprocedural management of anticoagulation. Suggested protocols are presented for bridge therapy...

  • When to Stop Anticoagulation Before Surgery? Elliott, William T. // Infectious Disease Alert;Mar2007, Vol. 26 Issue 6, p2 

    The article presents information on a study conducted by researchers from Ontario, Canada on when to stop anticoagulation for patients on warfarin who have been bridging therapy with low molecular weight heparin (LMWH) before surgery. Researchers observed 80 patients who were scheduled for...

  • When to Stop Anticoagulation Before Surgery? Elliott, William T. // Clinical Oncology Alert;Mar2007 Pharmacology Watch, p2 

    The article discusses research being done on when to stop anticoagulation before surgery. It references a study published in the 2007 issue of "Annals of Internal Medicine." Study researchers determined the best time to stop anticoagulation in patients on warfarin regimen who have been bridging...

  • DOSING CONVERSION FOR ANTICOAGULANTS: DABIGATRAN/HEPARIN/WARFARIN.  // Monthly Prescribing Reference;Jul2012, Vol. 28 Issue 7, p46 

    The article presents several measures that should be taken care before changing the doses of several anticoagulants including Dabigatran, Heparin and Warfarin. It focuses on the starting time of these drugs because it plays an important role in analyzing the effect of drugs. It presents...

  • Anticoagulant therapies: Review of available and upcoming agents. Tanzi, Maria G. // Pharmacy Today;Jan2011, Vol. 17 Issue 1, p58 

    Objectives: To identify clinical issues with warfarin therapy, differentiate between unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) and their respective advantages and disadvantages, explain the place in therapy for indirect and direct factor Xa inhibitors and direct...

  • Perioperative Management of Warfarin Therapy: To Bridge or Not to Bridge, That Is the Question. Douketis, James D. // Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p628 

    The article presents the author's perspective on a study concerning the perioperative practice of administering bridging anticoagulation with subcutaneous low-molecular-weight heparin (LMWH). He remarks that the novel aspect of the study is the inclusion of a comparison group of patients who did...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics